Activity of class A/B/D carbapenemases was determined by CarbaNP test (Dortet et al., 2012 (link)) with modifications. Overnight bacterial cell culture in MH broth was diluted 1:100 into 3 ml of fresh MH broth, and bacteria were allowed to grow at 37°C with shaking at 200 rpm to reach an OD600 of 1.0–1.4. If required, ampicillin was used at 200 μg/ml. Bacterial cells were harvested from 2 ml of the above culture, and washed twice with 20 mM Tris-HCl (pH 7.8). Cell pellets were resuspended in 500 μl of 20 mM Tris-HCl (pH 7.8), and lysed by soniation, followed by centrifugation at 10,000 ×g at 4 °C for 5 min. 50 μl of the supernatant (the enzymatic bacterial suspension) were mixed with 50 μl of substrate I to V, respectively, followed by incubation at 37°C for a maximum of 2 h. Substrate I: 0.054% phenol red plus 0.1 mM ZnSO4 (pH 7.8). Substrate II: 0.054% phenol red plus 0.1 mM ZnSO4 (pH 7.8), and 0.6 mg/μl imipenem. Substrate III: 0.054% phenol red plus 0.1 mM ZnSO4 (pH 7.8), 0.6 mg/μl mg imipenem, and 0.8 mg/μl tazobactam. Substrate IV: 0.054% phenol red plus 0.1 mM ZnSO4 (pH 7.8), 0.6 mg/μl mg imipenem, and 3 mM EDTA (pH 7.8). Substrate V: 0.054% phenol red plus 0.1 mM ZnSO4 (pH 7.8), 0.6 mg/μl mg imipenem, 0.8 mg/μl tazobactam, and 3 mM EDTA (pH 7.8).
>
Chemicals & Drugs
>
Antibiotic
>
Tazobactam
Tazobactam
Tazobactam is a beta-lactamase inhibitor that is often combined with the antibiotic piperacillin to enhance its antimicrobial activity.
It works by blocking the action of enzymes produced by bacteria that can break down and inactivate certain antibiotics.
This combination is commonly used to treat a variety of bacterial infections, including those caused by Gram-negative organisms.
Researchers can use PubCompare.ai to optimize their Tazobactam research by quickly identifying the most relevant scientific protocols and products from publications, preprints, and patents.
The AI-powered tool enhances reproducibility and accuracy, helping researchers find the best Tazobactam protocols for their needs.
It works by blocking the action of enzymes produced by bacteria that can break down and inactivate certain antibiotics.
This combination is commonly used to treat a variety of bacterial infections, including those caused by Gram-negative organisms.
Researchers can use PubCompare.ai to optimize their Tazobactam research by quickly identifying the most relevant scientific protocols and products from publications, preprints, and patents.
The AI-powered tool enhances reproducibility and accuracy, helping researchers find the best Tazobactam protocols for their needs.
Most cited protocols related to «Tazobactam»
Ampicillin
Bacteria
carbapenemase
Cell Culture Techniques
Cells
Centrifugation
Edetic Acid
Enzymes
Imipenem
Pellets, Drug
Tazobactam
Tromethamine
Activity of class A/B/D carbapenemases in bacterial cell extracts was determined via a modified CarbaNP test21 (link). Overnight bacterial cell culture in MH broth was diluted 1:100 into 3 ml of fresh MH broth, and bacteria were allowed to grow at 37 °C with shaking at 200 rpm to reach an OD600 of 1.0 to 1.4. If required, ampicillin was used at 200 μg/ml. Bacterial cells were harvested from 2 ml of the above culture, and washed twice with 20 mM Tris-HCl (pH 7.8). Cell pellets were resuspended in 500 μl of 20 mM Tris-HCl (pH 7.8), and lysed by soniation, followed by centrifugation at 10000 × g at 4 °C for 5 min. 50 μl of the supernatant (the enzymatic bacterial suspension) were mixed with 50 μl of substrate I to V, respectively, followed by incubation at 37 °C for a maximum of 2 h. Substrate I: 0.054% phenol red plus 0.1 mM ZnSO4 (pH7.8). Substrate II: 0.054% phenol red plus 0.1 mM ZnSO4 (pH7.8), and 0.6 mg/μl imipenem. Substrate III: 0.054% phenol red plus 0.1 mM ZnSO4 (pH7.8), 0.6 mg/μl mg imipenem, and 0.8 mg/μl tazobactam. Substrate IV: 0.054% phenol red plus 0.1 mM ZnSO4 (pH7.8), 0.6 mg/μl mg imipenem, and 3 mM EDTA (pH7.8). Substrate V: 0.054% phenol red plus 0.1 mM ZnSO4 (pH7.8), 0.6 mg/μl mg imipenem, 0.8 mg/μl tazobactam, and 3 mM EDTA (pH7.8).
Ampicillin
Bacteria
carbapenemase
Cell Culture Techniques
Cell Extracts
Cells
Centrifugation
Edetic Acid
Enzymes
Imipenem
Pellets, Drug
Tazobactam
Tromethamine
Kinetic parameters for hydrolysis of β-lactams by the purified OXA-830 β-lactamase were examined using a UV-VIS spectrophotometer (U-3900, HITACHI, Japan) at 30°C in 10 mM phosphate buffer (pH 7.0) in a final reaction volume of 300 μL. The steady-state kinetic parameters (kcat and KM) were determined by non-linear regression of the initial reaction rates with the Michaelis–Menten equation in Prism (version 7) software (GraphPad Software, San Jose, CA, United States).
β-lactamase inhibition was studied with benzylpenicillin (500 μM) as the substrate. The β-lactamase inhibitors sulbactam, tazobactam and clavulanic acid at various concentrations were preincubated with the purified OXA-830 β-lactamase for 3 min at 30°C before addition of substrate. The inhibitor concentration required to reduce the hydrolysis of 500 μM benzylpenicillin by 50% was determined by non-linear regression with the log(inhibitor) vs. response – Variable slope equation in Prism (version 7) software (GraphPad Software, San Jose, CA, United States).
β-lactamase inhibition was studied with benzylpenicillin (500 μM) as the substrate. The β-lactamase inhibitors sulbactam, tazobactam and clavulanic acid at various concentrations were preincubated with the purified OXA-830 β-lactamase for 3 min at 30°C before addition of substrate. The inhibitor concentration required to reduce the hydrolysis of 500 μM benzylpenicillin by 50% was determined by non-linear regression with the log(inhibitor) vs. response – Variable slope equation in Prism (version 7) software (GraphPad Software, San Jose, CA, United States).
beta-Lactamase
beta-Lactamase Inhibitors
Buffers
Clavulanic Acid
Hydrolysis
Kinetics
Lactams
Penicillin G
Phosphates
prisma
Psychological Inhibition
Sulbactam
Tazobactam
Library CCM-2 was plated at a density of about 500 CFU/cm2 (non-selective conditions) on LB-agar plates supplemented with 50 µg/ml Spec, 300 µM IPTG, 100 µg/ml ampicillin and 4 or 6 µg/ml tazobactam. Plates were incubated at 37°C for 17 hours. The tazobactam concentration chosen was 1.3 or 2-fold higher than the concentration at which cells bearing wildtype TEM-1 could grow effectively. Large colonies on the plates were chosen at random for sequencing.
Selected single base mutations were re-introduced into TEM-1 by site-directed PFunkel mutagenesis on the 20 µl volume scale. The MIC for ampicillin and piperacillin of the mutants was assessed with and without 6 µg/ml tazobactam by spotting 104 CFU on Mueller-Hinton agar plates containing 50 µg/ml Spec, 300 µM IPTG, and √2-fold increments of either ampicillin or piperacillin. Plates were incubated at 37°C for 12 hrs.
Selected single base mutations were re-introduced into TEM-1 by site-directed PFunkel mutagenesis on the 20 µl volume scale. The MIC for ampicillin and piperacillin of the mutants was assessed with and without 6 µg/ml tazobactam by spotting 104 CFU on Mueller-Hinton agar plates containing 50 µg/ml Spec, 300 µM IPTG, and √2-fold increments of either ampicillin or piperacillin. Plates were incubated at 37°C for 12 hrs.
Agar
Ampicillin
Cells
DNA Library
Isopropyl Thiogalactoside
Mutagenesis, Site-Directed
Mutation
Piperacillin
Tazobactam
Biopharmaceuticals
Ceftriaxone
Cholinergic Agents
Clavulanic Acid
Cocaine
Dopaminergic Agents
Drug Combinations
Dugesia
Glutamic Acid
Hyperkinesia
neuro-oncological ventral antigen 2, human
Opioids
Pharmaceutical Preparations
Planarians
Seizures
Tazobactam
Most recents protocols related to «Tazobactam»
Randomized participants were stratified and dosed by age group. The selected doses were based on population pharmacokinetic modeling and simulations.18 (link) For participants in the ceftolozane/tazobactam group, those 12 to <18 years of age were given 1.0 g ceftolozane and 0.5 g tazobactam (the dose indicated for adult patients with cUTI),15 and those from birth to <12 years of age were given 20 mg/kg ceftolozane and 10 mg/kg tazobactam (maximum of 1.0 g ceftolozane and 0.5 g tazobactam per dose). All participants in the meropenem group received 20 mg/kg (maximum of 1.0 g per dose), with higher dosing up to 30 mg/kg for participants who were 14 days to <3 months of age permitted at the investigator’s discretion. Each dose of ceftolozane/tazobactam or meropenem was administered as a 60-minute (±10 minutes) infusion and dosed every 8 hours (±1 hour) after the previous infusion.
Treatment duration was 7-14 days. After 3 days (9 doses) of IV therapy, optional open-label, standard-of-care, oral step-down therapy was permitted at the investigator’s discretion, with choice of therapy guided by culture and antibacterial susceptibility results, as well as local standard of care for treatment of cUTI. Recommended options for oral step-down therapy were β-lactam/β-lactamase inhibitor combinations, cephalosporins, fluoroquinolones, nitrofurantoin, trimethoprim‚ or trimethoprim/sulfamethoxazole.
Treatment duration was 7-14 days. After 3 days (9 doses) of IV therapy, optional open-label, standard-of-care, oral step-down therapy was permitted at the investigator’s discretion, with choice of therapy guided by culture and antibacterial susceptibility results, as well as local standard of care for treatment of cUTI. Recommended options for oral step-down therapy were β-lactam/β-lactamase inhibitor combinations, cephalosporins, fluoroquinolones, nitrofurantoin, trimethoprim‚ or trimethoprim/sulfamethoxazole.
Adult
Age Groups
Anti-Bacterial Agents
beta-Lactamase Inhibitors
Birth
ceftolozane
ceftolozane - tazobactam
Cephalosporins
Fluoroquinolones
Lactams
Meropenem
Nitrofurantoin
Patients
Susceptibility, Disease
Tazobactam
Therapeutics
Trimethoprim
Trimethoprim-Sulfamethoxazole Combination
A 75-year-old woman was admitted on 13 May 2021 to a University Hospital in Rio de Janeiro, Brazil, due to an arterial ulcer in the left foot (Fontaine IV Peripheral Arterial Disease). The disease started a year before and clinical treatments were unsuccessful, leading to bone exposure. Therefore, she was being prepared for a surgical amputation. Positive polymerase chain reaction results from two nasal swabs for SARS-CoV-2 was found twice, 30 and 10 days before admission, and she was treated symptomatically at home. Remarkable data in her past pathological history are systemic arterial hypertension, stroke with resulting aphasia and past history of smoking. She was started on intravenous antimicrobials (piperacillin and tazobactam) and heart monitoring due to the atrial fibrillation. Her general condition worsened quickly, showing drowsiness with disorientation, bradycardia and hypotension, metabolic acidosis, leukocytosis and elevated C-reactive protein. At that time, a nasal swab antigen test did not detect SARS-CoV-2. Two blood samples were collected and sent to the laboratory for culture approximately 6 hours before she died due to the septic shock, 4 days after hospitalization, on 17 May 2021. Yeast-like organisms were isolated from both blood culture samples (Figure 1 A).
Acidosis, Metabolic
Amputation
Antigens
Aphasia
Arteries
Atrial Fibrillation
BLOOD
Blood Culture
Bones
Cerebrovascular Accident
C Reactive Protein
Foot Ulcer
Heart
High Blood Pressures
Hospitalization
Leukocytosis
Microbicides
Nose
Peripheral Vascular Diseases
Piperacillin
Polymerase Chain Reaction
SARS-CoV-2
Septic Shock
Somnolence
Tazobactam
Woman
Yeast, Dried
The MICs of PIS, PTZ, and CSL were determined at our laboratory by the agar dilution method according to Clinical and Laboratory Standards Institute (CLSI) guidelines (Thirty-Second Informational Supplement: M100-S32). PIS and CSL were prepared at a ratio of 2:1, and tazobactam in PTZ was used at a fixed concentration of 4 mg/L. Plates were incubated at 35 °C for 16–20 h. E. coli ATCC 25922 and P. aeruginosa ATCC 27853 were the quality-control strains.
CLSI criteria were used to interpret the results according to the interpretive standards for PTZ (Enterobacteriaceae: ≤8/4 mg/L = sensitive, ≥32/4 mg/L = resistant; P. aeruginosa and A. baumannii: ≤16/4 mg/L = sensitive, ≥128/4 mg/L = resistant), and PIS (Enterobacteriaceae: ≤8/4 mg/L = sensitive, ≥32/16 mg/L = resistant; P. aeruginosa: ≤16/8 mg/L = sensitive, ≥128/64 mg/L = resistant) [5 (link)]. The FDA criteria for cefoperazone was used to interpret the results for CSL (Enterobacteriaceae and P. aeruginosa: ≤16/8 mg/L = sensitive, ≥64/32 mg/L = resistant). For PIS and CSL against A. baumannii, the CLSI criteria for sulbactam within ampicillin/sulbactam (≤4 mg/L = sensitive and ≥16 mg/L = resistant) were used [20 ].
CLSI criteria were used to interpret the results according to the interpretive standards for PTZ (Enterobacteriaceae: ≤8/4 mg/L = sensitive, ≥32/4 mg/L = resistant; P. aeruginosa and A. baumannii: ≤16/4 mg/L = sensitive, ≥128/4 mg/L = resistant), and PIS (Enterobacteriaceae: ≤8/4 mg/L = sensitive, ≥32/16 mg/L = resistant; P. aeruginosa: ≤16/8 mg/L = sensitive, ≥128/64 mg/L = resistant) [5 (link)]. The FDA criteria for cefoperazone was used to interpret the results for CSL (Enterobacteriaceae and P. aeruginosa: ≤16/8 mg/L = sensitive, ≥64/32 mg/L = resistant). For PIS and CSL against A. baumannii, the CLSI criteria for sulbactam within ampicillin/sulbactam (≤4 mg/L = sensitive and ≥16 mg/L = resistant) were used [20 ].
Agar
ampicillin-sulbactam
Cefoperazone
Clinical Laboratory Services
Clinical Laboratory Techniques
Dietary Supplements
Enterobacteriaceae
Escherichia coli
Minimum Inhibitory Concentration
Pseudomonas aeruginosa
Strains
Sulbactam
Tazobactam
Technique, Dilution
Piperacillin (potency 95%, lot no. P1200717), sulbactam (potency 91%, lot no. 03191203), and tazobactam (potency 95%, lot no. 03191203) were purchased from Suzhou Erye Pharmaceutical Co. Cefoperazone (potency 99%, lot no. 130420-201105) was purchased from the National Institutes for Food and Drug Control. Mueller–Hinton agar (MHA) was purchased from OXOID (UK, lot no. 2989738).
Agar
Cefoperazone
Food
Pharmaceutical Preparations
Piperacillin
Sulbactam
Tazobactam
Sulbactam sodium, tazobactam, meropenem trihydrate, metronidazole, ampicillin sodium, cefotaxime sodium, cefoperazone sodium, piperacillin sodium, and acetaminophen were all purchased from Macklin (Shanghai, China). ULC–MS grade acetonitrile and methanol were supplied from the Anaqua™ Chemicals Supply (Wilmington, NC, USA). ULC–MS grade formic acid and ammonium formate were purchased from Macklin (Shanghai, China). Deionized water was purified using a Hitech Smart-S ultrapure water system (Shanghai, China). Whole blood was obtained from drug-free healthy volunteers and collected in heparin sodium tubes.
Acetaminophen
acetonitrile
BLOOD
formic acid
formic acid, ammonium salt
Healthy Volunteers
Heparin Sodium
Meropenem
Methanol
Metronidazole
Pharmaceutical Preparations
Sodium, Ampicillin
Sodium, Cefoperazone
Sodium, Cefotaxime
Sodium, Piperacillin
Sulbactam Sodium
Tazobactam
Top products related to «Tazobactam»
Sourced in United States, Germany, Belgium, Sao Tome and Principe, United Kingdom
Tazobactam is a beta-lactamase inhibitor used in combination with certain antibiotics to enhance their efficacy. It functions by inhibiting the activity of beta-lactamase enzymes produced by some bacteria, which can otherwise degrade and render certain antibiotics ineffective.
Sourced in United States, United Kingdom, Switzerland, Canada, Sao Tome and Principe, Germany
Piperacillin is a semisynthetic penicillin antibiotic. It is used as a broad-spectrum antibiotic to treat a variety of bacterial infections.
Sourced in United States, Germany, France, China, Sao Tome and Principe, United Kingdom, Italy, India, Spain, Brazil, Canada
Imipenem is a broad-spectrum antibiotic medication used to treat various bacterial infections. It is a member of the carbapenem class of antibiotics and functions by inhibiting bacterial cell wall synthesis, leading to cell death.
Sourced in Japan
Tazobactam is a beta-lactamase inhibitor. It is used in combination with other antibacterial agents to enhance their effectiveness against certain bacteria that produce beta-lactamase enzymes.
Sourced in United States, Germany, United Kingdom, France, China, Switzerland, Sao Tome and Principe, Spain, Ireland, India, Italy, Japan, Brazil, Australia, Canada, Macao, Czechia, New Zealand, Belgium, Cameroon, Austria, Israel, Norway, Denmark, Netherlands
Ampicillin is a broad-spectrum antibiotic used in laboratory settings. It is a penicillin-based compound effective against a variety of gram-positive and gram-negative bacteria. Ampicillin functions by inhibiting cell wall synthesis, leading to bacterial cell lysis and death.
Sourced in United States, Germany, United Kingdom, Spain, India, China
Ertapenem is a broad-spectrum carbapenem antibiotic developed by Merck Group for the treatment of various bacterial infections. It functions as an inhibitor of cell wall synthesis in susceptible bacteria.
Sourced in United States, Germany, United Kingdom, Switzerland, Sao Tome and Principe, France, Belgium
Cefotaxime is a third-generation cephalosporin antibiotic used in laboratory settings. It is a broad-spectrum antibiotic effective against a variety of Gram-positive and Gram-negative bacteria.
Sourced in India
Ceftriaxone is a broad-spectrum cephalosporin antibiotic. It is a sterile, crystalline powder used for the preparation of injectable solutions.
Sourced in United States, United Kingdom, Germany, Sao Tome and Principe, Canada, China, Australia, Spain
Ceftazidime is a broad-spectrum cephalosporin antibiotic that belongs to the beta-lactam class of antibiotics. It is used in the treatment of a variety of bacterial infections. Ceftazidime functions by inhibiting the synthesis of the bacterial cell wall, thereby causing cell lysis and death.
Sourced in United States, Germany, Australia, France
Aztreonam is a synthetic monocyclic beta-lactam antibiotic that is primarily used as a treatment for gram-negative bacterial infections. It functions by inhibiting bacterial cell wall synthesis, thus preventing the growth and multiplication of susceptible organisms.
More about "Tazobactam"
Tazobactam is a beta-lactamase inhibitor that is often combined with the antibiotic piperacillin to enhance its antimicrobial activity.
It works by blocking the action of enzymes produced by bacteria that can break down and inactivate certain antibiotics, such as imipenem, ampicillin, ertapenem, cefotaxime, ceftriaxone, and ceftazidime.
This combination is commonly used to treat a variety of bacterial infections, including those caused by Gram-negative organisms like Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
Researchers can use PubCompare.ai to optimize their Tazobactam research by quickly identifying the most relevant scientific protocols and products from publications, preprints, and patents.
The AI-powered tool enhances reproducibility and accuracy, helping researchers find the best Tazobactam protocols for their needs, whether they're studying the synergistic effects of Tazobactam with antibiotics like aztreonam or exploring new applications for this versatile beta-lactamase inhibitor.
It works by blocking the action of enzymes produced by bacteria that can break down and inactivate certain antibiotics, such as imipenem, ampicillin, ertapenem, cefotaxime, ceftriaxone, and ceftazidime.
This combination is commonly used to treat a variety of bacterial infections, including those caused by Gram-negative organisms like Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
Researchers can use PubCompare.ai to optimize their Tazobactam research by quickly identifying the most relevant scientific protocols and products from publications, preprints, and patents.
The AI-powered tool enhances reproducibility and accuracy, helping researchers find the best Tazobactam protocols for their needs, whether they're studying the synergistic effects of Tazobactam with antibiotics like aztreonam or exploring new applications for this versatile beta-lactamase inhibitor.